Diagnosis and treatment of MPN in real life: exploratory and retrospective chart review including 960 MPN patients diagnosed with ET or MF in Germany

Autor: Andreas Schmidt, Christiane Bernhardt, Dieter Bürkle, Stefan Fries, Carla V. Hannig, Kathleen Jentsch-Ullrich, Andreas Josting, Stephan Kreher, Marcel Reiser, Hans Tilman Steinmetz, Hans Tesch, Stephanie Terner, Alexander Schulte, Carl C. Crodel, Francesca Palandri, Florian H. Heidel

Publikováno v: Journal of Cancer Research and Clinical Oncology.

Purpose The WHO 2016 re-classification of myeloproliferative neoplasms resulted in a separation of essential thrombocythemia (ET) from the pre-fibrotic and fibrotic (overt) phases of primary myelofibrosis (MF). This study reports on a chart review co

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_________::2402753fbd4a42451f00ece87c21466c
https://doi.org/10.1007/s00432-023-04669-3

Treatment of Immune Thrombocytopenia (ITP) with Eltrombopag - Results of the 3rd Interim Analysis of the German Non-Interventional Trial RISA

Autor: Andreas Josting, Dietrich Kaempfe, Nadine Ballerstädt, Petra Stark-Lorenzen, Oliver Meyer, Martina Stauch, Margarete Plath, Eyck von der Heyde, Rudolf Schlag, M. Reiser, Axel Matzdorff

Publikováno v: Blood. 136:1-2

Background:Immune thrombocytopenia (ITP) is an acquired autoimmune disorder, characterized by increased platelet destruction and impaired platelet production. Therefore, affected patients present with bleeding complications of various severity. Howev

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_________::2c0b3ad86987de8257449d84446584e8
https://doi.org/10.1182/blood-2020-134542

Epoetin Alfa in Patients With Advanced-Stage Hodgkin's Lymphoma: Results of the Randomized Placebo-Controlled GHSG HD15EPO Trial

Autor: Heinz Haverkamp, Martin Vogelhuber, Andreas Lohri, Michael Fuchs, Lucia Nogova, Martin Sökler, Josée M. Zijlstra, Max S. Topp, Peter Borchmann, Hans-Henning Flechtner, Volker Diehl, Matthias Villalobos, Thorsten Zenz, Isrid Sturm, Andreas Rank, Andreas Engert, Andreas Josting

Publikováno v: Engert, A, Josting, A, Haverkamp, H, Villalobos, M, Lohri, A, Sokler, M, Zijlstra-Baalbergen, J M, Sturm, I, Topp, M S, Rank, A, Zenz, T, Vogelhuber, M, Nogova, L, Borchmann, P, Fuchs, M, Flechtner, H H & Diehl, V 2010, ' Epoetin Alfa in Patients With Advanced-Stage Hodgkin's Lymphoma: Results of the Randomized Placebo-Controlled GHSG HD15EPO Trial ', Journal of Clinical Oncology, vol. 28, no. 13, pp. 2239-2245 . https://doi.org/10.1200/JCO.2009.25.1835
Journal of Clinical Oncology, 28(13), 2239-2245. American Society of Clinical Oncology

Purpose To determine whether epoetin alfa reduces anemia-related fatigue, improves other aspects of health-related patient-recorded outcomes (PROs), reduces the number of RBC transfusions, and has an impact on freedom from treatment failure (FFTF) an

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::528e2fb963f78667c848c8e41ba6e607
https://doi.org/10.1200/jco.2009.25.1835

Rituximab added to an intensified salvage chemotherapy program followed by autologous stem cell transplantation improved the outcome in relapsed and refractory aggressive non-Hodgkin lymphoma

Autor: Helena Scheuß, Jan-Peter Glossmann, Thorsten Reineke, Andreas Engert, Volker Diehl, Oliver Staak, Michal Sieniawski, Andreas Josting

Publikováno v: Annals of Hematology. 86:107-115

We investigated the addition of rituximab to an intensified salvage program followed by a myeloablative course with autologous stem cell transplantation (ASCT) in patients with relapsed or refractory aggressive non-Hodgkin lymphoma (NHL). Patients wi

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::fe429d2c2d07a8564295edda527097d6
https://doi.org/10.1007/s00277-006-0210-5

Role of Hematotoxicity and Sex in Patients With Hodgkin's Lymphoma: An Analysis From the German Hodgkin Study Group

Autor: Heinz Haverkamp, Hans Theodor Eich, Thorsten Reineke, Volker Diehl, Andreas Josting, Beate Pfistner, Andreas Engert, Karolin Behringer, Beate Klimm

Publikováno v: Journal of Clinical Oncology. 23:8003-8011

Purpose Several scores have described sex as a prognostic factor in patients with Hodgkin's lymphoma (HL). However, little is known how sex-specific factors influence treatment outcome. We systematically investigated sex differences with regard to pr

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::b3ea2c94097b9fe5c309a0e3055659bb
https://doi.org/10.1200/jco.2005.205.60